Background: Airway eosinophilia and Th2 lymphocytes-recruitment to the lung are one of the main pathological features of asthma. It is clear now that the axis chemokine/chemokine receptors have a role in controlling leukocyte recruitment and development of the inflammatory process observed in asthma. Although it has been reported that CCR9 receptor is expressed in asthmatic patients, it is not known whether CCR9 may have a regulatory role of the development of this disease. Our aim was to analyze the expression of CCR9 in a murine model of allergic airway inflammation (WT) and compared to CCR9 deficient (KO) mice. Methods: Four groups of 6 to 8 weeks female CCR9-deficient mice were sensitized by intraperitoneal injections of 10 micrograms of ovalbumin (OVA) in alum (ALOH3) diluted in PBS, on days 1 and 8 of the established sensitization protocol. Aerosolised OVA was administered (1% in PBS) on days 15, 20 and 34. 24 hours after last OVA exposure, mice were sacrificed and bronchoalveolar lavage (BAL) fluid and cells were obtained. Total and differential cell numbers were obtained and characterized cell subpopulations by FACS analysis. Cytokine/chemokine levels were quantified by ELISA and qRT-PCR respectively. Results: Total cell numbers in BAL were no significantly different between WT and KO mice. Interestingly, reduction in the numbers of eosinophils was observed in CCR9 KO mice compared to WT mice. Histological analysis of lung tissue demonstrated a reduction in the granulocytic population (eosinophils) in CCR9 KO mice. Analysis of cell subpopulations by FACS demonstrated that CD41 lymphocytes were significantly reduced but CD81 and CD191 lymphocytes numbers were not different between WT and CCR9-deficient mice. A population of CCR91 Gr11 was altered in KO mice and it correlated with cytological analysis. Furthermore, histological analysis demonstrated alteration in mucus production in allergic airway in CCR9 deficient mice, accompanied with a no-significant reduction of OVAspecific anti-IgE antibodies in serum at the time of analysis. Conclusions: Altogether, these results suggest that CCR9 may be involved in recruitment of granulocytic cell subpopulation into the allergic airways and have an impact in the regulation of the chronic inflammatory process. 3 Center for Genomics and Personalized Medicine Research, Wake Forest University Health Sciences, Winston-Salem, NC. Background: Interleukin 6 (IL6) belongs to a family of cytokines with both pro-and anti-inflammatory properties. The functional relationship between IL6 signaling and airway disease has not be well characterized; however, IL6 expression is increased during lung inflammation and injury. In this study, serum IL6 and soluble IL6R levels were assessed in non-Hispanic whites with asthma from the Severe Asthma Research Program. Correlations between serum IL6 and IL6R levels, lung function, phenotypic asthma clusters, and asthma severity were evaluated. Methods: Serum IL6 and soluble IL6R was measured in 149 subjects with mild to severe asthma. Serum sIL6R levels were measured using the sIL-6R DuoSet (R&D Systems, Minneapolis, MN) ELISA kit and reported as ng/ml. Serum IL6 measurements were determined using the IL-6 ELISA kit (R&D Systems, Minneapolis, MN) and reported as pg/ml. Serum IL6 and sIL6R measurements were transformed to normalize distribution. The continuous variables analyzed included: % predicted FEV 1 [ppFEV 1 ], % predicted FVC [ppFVC], and FEV 1 /FVC. Serum samples were collected at Wake Forest. Phenotypic asthma clusters were derived as previously described (Am J Respir Crit Care Med. 2010;181:315-323). Results: Elevated serum IL6 was associated with lower ppFEV 1 (P ¼ 0.02) and lower ppFVC (P ¼ 0.003), while elevated serum soluble IL6R was associated with lower ppFEV 1 (P ¼ 0.02) and lower ppFVC (P ¼ 0.008). Increasing trends in serum IL6 were observed in atopic asthma Clusters 2 and 4 and the later onset fixed airways obstruction Cluster 5. The highest IL6 serum levels were observed in Cluster 3 characterized has having late onset asthma and elevated BMI. Serum IL6 levels were elevated in subjects with severe asthma (log IL6 ¼ 0.33; N ¼ 25) compared to subjects with mild/ moderate asthma (log IL6 ¼ 0.16; N ¼ 69). Conclusions: Serum IL6 and sIL6R levels are elevated in non-Hispanic white asthma subjects with lower lung function. Serum IL6 and sIL6R are potentially important biomarkers that may distinguish between non-severe and severe asthma and between atopic asthma Clusters. Background: Peptide-based allergen immunotherapy is a promising alternative to conventional allergy vaccine. However, the optimal composition of such vaccines, in terms of the choice of the appropriate peptides, has remained unclear. Knowledge of the epitope-specific T cell responses to allergens can give important information on the pathogenesis and regulation of allergic inflammation. In this study we sought to identify candidate allergen-epitopes that can be used to improve peptide-based allergen immunotherapy. Methods: Tetramer Guided Epitope Mapping was first used to identify CD41 T cell epitopes for group 1 and group 5 timothy grass pollen allergens. MHC class II tetramer technology was then used in an ex vivo approach to assess the grass pollen-specific CD4 1 T cell responses in allergic and nonallergic individuals. The frequency, surface marker phenotype and cytokine profile of these cells were directly analysed by flow cytometry.
3 Center for Genomics and Personalized Medicine Research, Wake Forest University Health Sciences, Winston-Salem, NC. Background: Interleukin 6 (IL6) belongs to a family of cytokines with both pro-and anti-inflammatory properties. The functional relationship between IL6 signaling and airway disease has not be well characterized; however, IL6 expression is increased during lung inflammation and injury. In this study, serum IL6 and soluble IL6R levels were assessed in non-Hispanic whites with asthma from the Severe Asthma Research Program. Correlations between serum IL6 and IL6R levels, lung function, phenotypic asthma clusters, and asthma severity were evaluated. Methods: Serum IL6 and soluble IL6R was measured in 149 subjects with mild to severe asthma. Serum sIL6R levels were measured using the sIL-6R DuoSet (R&D Systems, Minneapolis, MN) ELISA kit and reported as ng/ml. Serum IL6 measurements were determined using the IL-6 ELISA kit (R&D Systems, Minneapolis, MN) and reported as pg/ml. Serum IL6 and sIL6R measurements were transformed to normalize distribution. The continuous variables analyzed included: % predicted FEV 1 [ppFEV 1 ], % predicted FVC [ppFVC] , and FEV 1 /FVC. Serum samples were collected at Wake Forest. Phenotypic asthma clusters were derived as previously described (Am J Respir Crit Care Med. 2010; 181:315-323) . Results: Elevated serum IL6 was associated with lower ppFEV 1 (P ¼ 0.02) and lower ppFVC (P ¼ 0.003), while elevated serum soluble IL6R was associated with lower ppFEV 1 (P ¼ 0.02) and lower ppFVC (P ¼ 0.008). Increasing trends in serum IL6 were observed in atopic asthma Clusters 2 and 4 and the later onset fixed airways obstruction Cluster 5. The highest IL6 serum levels were observed in Cluster 3 characterized has having late onset asthma and elevated BMI. Serum IL6 levels were elevated in subjects with severe asthma (log IL6 ¼ 0.33; N ¼ 25) compared to subjects with mild/ moderate asthma (log IL6 ¼ 0.16; N ¼ 69). Conclusions: Serum IL6 and sIL6R levels are elevated in non-Hispanic white asthma subjects with lower lung function. Serum IL6 and sIL6R are potentially important biomarkers that may distinguish between non-severe and severe asthma and between atopic asthma Clusters. Background: Peptide-based allergen immunotherapy is a promising alternative to conventional allergy vaccine. However, the optimal composition of such vaccines, in terms of the choice of the appropriate peptides, has remained unclear. Knowledge of the epitope-specific T cell responses to allergens can give important information on the pathogenesis and regulation of allergic inflammation. In this study we sought to identify candidate allergen-epitopes that can be used to improve peptide-based allergen immunotherapy. Methods: Tetramer Guided Epitope Mapping was first used to identify CD41 T cell epitopes for group 1 and group 5 timothy grass pollen allergens. MHC class II tetramer technology was then used in an ex vivo approach to assess the grass pollen-specific CD4 1 T cell responses in allergic and nonallergic individuals. The frequency, surface marker phenotype and cytokine profile of these cells were directly analysed by flow cytometry.
MECHANISMS OF ASTHMA AND ALLERGIC INFLAMMATION
Results: CD41 T cell responses to Timothy grass allergens are directed to a broad range of epitopes characterized by defined immunodominance hierarchy patterns. We observed heterogeneity of phenotype within the allergenspecific CD41 T cells that depends on the epitope for which the cells are specific. T cell epitopes associated with production of IL-10 or IFN-g are recognized at low frequencies in both allergic and healthy individuals. In contrast, allergy-associated epitopes are only recognized in allergic individuals by high frequency, terminally differentiated allergen-specific CD41 T cells, which are susceptible to deletion by repeated stimulation with high doses of antigen. Allergen-specific immunotherapy caused significant changes in the epitopes hierarchy of the grass pollen allergen-specific memory CD4 T cell pool. Conclusions: The ability to evaluate epitope-specific T cell responses to allergens can give important information on the pathogenesis and regulation of allergic inflammation and could be of great use in designing peptide-based allergy vaccination strategies. Some epitopes may play a prominent role in
